Exact Sciences Corp (EXAS):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Exact Sciences Corp (EXAS) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7336
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Exact Sciences Corp (Exact Sciences) is a molecular diagnostic company that focuses on the early detection and prevention of various types of cancers. The company’s flagship product, Cologuard test is a non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of colorectal cancer and pre-cancer. It utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer. The company is also working on the development of additional tests for other types of cancers and identified proprietary methylation markers for several major cancers. It operates laboratory facilities in Madison, Wisconsin to process Cologuard tests. Exact Sciences is headquartered in Madison, Wisconsin, the US.

Exact Sciences Corp (EXAS) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Exact Sciences Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Exact Sciences Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Exact Sciences Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Exact Sciences Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Exact Sciences Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Exact Sciences Corp, Medical Equipment, Deal Details 11
Asset Purchase 11
Exact Science to Acquire Biomarker and Technology Patents from MdxHealth for USD15 Million 11
Venture Financing 12
Armune BioScience Raises USD0.5 Million in Venture Financing 12
Armune BioScience Raises USD5 Million in Series A Venture Financing 13
Armune BioScience Raises USD4 Million in Second and Final Tranche of Series A Financing 14
Armune BioScience to Raise USD25 Million in Series B Financing 15
Armune BioScience Raises Additional USD5.6 Million in Venture Financing 16
Armune Biosciences Raises USD2.5 Million in Series A Venture Financing 17
Armune BioScience Raises USD3.5 Million in Venture Financing 18
Armune BioScience Raises US$1.4 Million In Venture Financing 19
Partnerships 20
Exact Sciences and Pfizer Enter into Co-Promotion Agreement 20
MDxHealth Enters into Agreement with Exact Sciences 21
Aeterna Zentaris Expands its Co-Marketing Agreement with Armune BioScience 22
Equity Offering 23
Exact Sciences Raises USD245 Million in Public Offering of Shares 23
Exact Sciences Prices Public Offering of Shares for USD132 Million 25
Exact Sciences Prices Public Offering of Shares for USD178.5 Million 26
Exact Sciences Prices Public Offering of Shares for USD103 Million 27
Exact Sciences Completes Public Offering Of Shares For US$146.6 Million 28
Exact Sciences Completes Public Offering Of Shares For US$78 Million 30
Exact Sciences Completes Public Offering of Common Stock For US$62 Million 31
Debt Offering 32
Exact Sciences Prices Public Offering of 1% Convertible Senior Notes Due 2025 for USD190 Million 32
Exact Sciences Raises USD690 Million in Public Offering of Senior Notes Due 2025 33
Acquisition 34
Exact Sciences Acquires Armune Bioscience 34
Exact Sciences Corp – Key Competitors 35
Exact Sciences Corp – Key Employees 36
Exact Sciences Corp – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Strategy And Business Planning 39
Aug 14, 2018: University Research Park Breaks Ground on Corporate Headquarters Building for Exact Sciences 39
Financial Announcements 40
Jan 07, 2018: Exact Sciences to report $265.5-266.5 million in revenue, 168 percent growth for 2017 40
Jul 25, 2017: Cologuard revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests 41
Feb 21, 2017: Exact Sciences reports lower Q4 net loss, provides outlook for 2017 42
Other Significant Developments 43
Aug 23, 2018: Exact Sciences and Pfizer to co-market colorectal cancer diagnosis test 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Exact Sciences Corp, Medical Equipment, Key Facts, 2017 2
Exact Sciences Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Exact Sciences Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Exact Sciences Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Exact Sciences Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Exact Sciences Corp, Deals By Market, 2012 to YTD 2018 9
Exact Sciences Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Exact Science to Acquire Biomarker and Technology Patents from MdxHealth for USD15 Million 11
Armune BioScience Raises USD0.5 Million in Venture Financing 12
Armune BioScience Raises USD5 Million in Series A Venture Financing 13
Armune BioScience Raises USD4 Million in Second and Final Tranche of Series A Financing 14
Armune BioScience to Raise USD25 Million in Series B Financing 15
Armune BioScience Raises Additional USD5.6 Million in Venture Financing 16
Armune Biosciences Raises USD2.5 Million in Series A Venture Financing 17
Armune BioScience Raises USD3.5 Million in Venture Financing 18
Armune BioScience Raises US$1.4 Million In Venture Financing 19
Exact Sciences and Pfizer Enter into Co-Promotion Agreement 20
MDxHealth Enters into Agreement with Exact Sciences 21
Aeterna Zentaris Expands its Co-Marketing Agreement with Armune BioScience 22
Exact Sciences Raises USD245 Million in Public Offering of Shares 23
Exact Sciences Prices Public Offering of Shares for USD132 Million 25
Exact Sciences Prices Public Offering of Shares for USD178.5 Million 26
Exact Sciences Prices Public Offering of Shares for USD103 Million 27
Exact Sciences Completes Public Offering Of Shares For US$146.6 Million 28
Exact Sciences Completes Public Offering Of Shares For US$78 Million 30
Exact Sciences Completes Public Offering of Common Stock For US$62 Million 31
Exact Sciences Prices Public Offering of 1% Convertible Senior Notes Due 2025 for USD190 Million 32
Exact Sciences Raises USD690 Million in Public Offering of Senior Notes Due 2025 33
Exact Sciences Acquires Armune Bioscience 34
Exact Sciences Corp, Key Competitors 35
Exact Sciences Corp, Key Employees 36
Exact Sciences Corp, Subsidiaries 38

List of Figures
Exact Sciences Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Exact Sciences Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Exact Sciences Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Exact Sciences Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Exact Sciences Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Exact Sciences Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Exact Sciences Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Exact Sciences Corp, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Exact Sciences Corp (EXAS):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cargolux Airlines International S.A.:企業の戦略・SWOT・財務情報
    Cargolux Airlines International S.A. - Strategy, SWOT and Corporate Finance Report Summary Cargolux Airlines International S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • PT Garuda Indonesia (Persero) Tbk:企業の戦略・SWOT・財務情報
    PT Garuda Indonesia (Persero) Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Garuda Indonesia (Persero) Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • NXP Semiconductors NV (NXPI):企業の財務・戦略的SWOT分析
    NXP Semiconductors NV (NXPI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Extendicare Inc.:企業の戦略・SWOT・財務分析
    Extendicare Inc. - Strategy, SWOT and Corporate Finance Report Summary Extendicare Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • TAP Biosystems Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary TAP Biosystems Ltd (TAP), a subsidiary of Sartorius Stedim Biotech GmbH is a provider of laboratory and pharmaceutical equipment. The company designs and manufactures automated cell culture, bio-reactor systems and fermentation systems. It also provides labware, consumables and accessories. …
  • Kotak Wealth Management:企業の戦略・SWOT・財務分析
    Kotak Wealth Management - Strategy, SWOT and Corporate Finance Report Summary Kotak Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Infinity Pharmaceuticals Inc (INFI):企業の財務・戦略的SWOT分析
    Infinity Pharmaceuticals Inc (INFI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Banco do Nordeste SA:企業の戦略・SWOT・財務分析
    Banco do Nordeste SA - Strategy, SWOT and Corporate Finance Report Summary Banco do Nordeste SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Altimmune Inc-製薬・医療分野:企業M&A・提携分析
    Summary Altimmune Inc (Altimmune), formerly Vaxin Inc is a biotechnology company that develops vaccines and other biological products. The company's products include novel vaccine delivery platforms, immunotherapeutic products, intranasally administered recombinant influenza vaccine, traditional inf …
  • China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999):企業の財務・戦略的SWOT分析
    China Resources Sanjiu Medical & Pharmaceutical Co Ltd (000999) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the …
  • Bolsas y Mercados Espanoles SA (BME):企業の財務・戦略的SWOT分析
    Summary Bolsas y Mercados Espanoles SA (BME) is an investment service provider that operates financial system. The company is an operator of financial systems. It offers services, products and advanced trading and global market access systems to issuers, intermediaries and investors. BME also offers …
  • Linde AG (LIN)-医療機器分野:企業M&A・提携分析
    Summary Linde AG (Linde) is a provider of industrial gases and engineering services. The company specializes in the planning, procurement, construction and operation of gas production and processing plants. Linde offers a wide range of compressed and liquefied gases, and chemicals, and offers facili …
  • Varian Medical Systems Inc (VAR):企業の財務・戦略的SWOT分析
    Varian Medical Systems Inc (VAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Jeil Pharmaceutical Co Ltd (002620):企業の財務・戦略的SWOT分析
    Jeil Pharmaceutical Co Ltd (002620) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Avery Dennison Corporation (AVY):企業の財務・戦略的SWOT分析
    Avery Dennison Corporation (AVY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Telekom Slovenije, d.d. (TLSG):企業の財務・戦略的SWOT分析
    Telekom Slovenije, d.d. (TLSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • ITM Power Plc (ITM):電力:M&Aディール及び事業提携情報
    Summary ITM Power Plc (ITM Power) is a renewable energy company. It designs and manufactures hydrogen energy systems for clean fuel production and energy storage. The company develops equipment to convert renewable energy into a clean fuel that can be stored for use in transport, industrial, and res …
  • OraSure Technologies Inc (OSUR)-医療機器分野:企業M&A・提携分析
    Summary OraSure Technologies Inc (OraSure) is a manufacturer and distributor of oral fluid specimen collection devices, diagnostic products and other medical devices. Its product portfolio encompasses infectious disease tests for the detection of antibodies for the HIV and Hepatitis C virus; and ant …
  • Apexigen Inc-製薬・医療分野:企業M&A・提携分析
    Summary Apexigen Inc (Apexigen) is a clinical-stage biopharmaceutical company t hat focuses on discovery and development of antibody-based drugs for the treatment of cancer.The company’s lead immune oncology program APX005M, is a humanized monoclonal antibody that stimulates cancer specific T-cell r …
  • Memorial Sloan Kettering Cancer Center:企業のM&A・事業提携・投資動向
    Memorial Sloan Kettering Cancer Center - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Memorial Sloan Kettering Cancer Center Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed repo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆